Levetiracetam
- Generic Name
- Levetiracetam
- Brand Names
- Elepsia, Keppra, Matever, Roweepra, Spritam, Levetiracetam Accord, Levetiracetam Teva, Levetiracetam Actavis, Levetiracetam ratiopharm, Levetiracetam Sun, Levetiracetam Actavis Group, Levetiracetam Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N2O2
- CAS Number
- 102767-28-2
- Unique Ingredient Identifier
- 44YRR34555
- Background
Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs). Levetiracetam possesses a wide therapeutic index and little-to-no potential t...
- Indication
Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seiz...
- Associated Conditions
- Epilepsies, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Myoclonic seizures
- Associated Therapies
- -
Levetiracetam 750 mg Tablets Under Non-Fasting Conditions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT00849485
- Locations
- 🇨🇦
SFBC Anapharm, Sainte-Foy, Quebec, Canada
Levetiracetam 750 mg Tablets Under Fasting Conditions
- First Posted Date
- 2009-02-24
- Last Posted Date
- 2009-09-11
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 22
- Registration Number
- NCT00849862
- Locations
- 🇨🇦
SFBC-Anapharm, Sainte-Foy, Quebec, Canada
Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions
- Conditions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 26
- Registration Number
- NCT00827320
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions
- Conditions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 30
- Registration Number
- NCT00826722
- Locations
- 🇺🇸
Novum Pharmaceutical Research Services, Houston, Texas, United States
Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions
- Conditions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 27
- Registration Number
- NCT00826865
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions
- Conditions
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Roxane Laboratories
- Target Recruit Count
- 29
- Registration Number
- NCT00826787
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
Antiepileptic Drugs and Vascular Risk Markers
- Conditions
- Interventions
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 52
- Registration Number
- NCT00774306
Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam
- Conditions
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT00736931
Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy
- Conditions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 342
- Registration Number
- NCT00643500
Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy
- First Posted Date
- 2008-03-07
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 3
- Registration Number
- NCT00630630
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.